Ophthalmology Innovation Center
Naj Sharif, PhD, DSc has more than 34-years’ pharmaceutical drug discovery research/development experience covering neuroscience and ophthalmology. His 22-year tenure at Alcon resulted in his contributions to the discovery, characterization, development and US FDA approvals of Patanol®/Pataday®/Pazeo® and Emadine® to treat allergic conjunctivitis, and Travatan® and Simbrinza® for the treatment of ocular hypertension / Glaucoma. Currently, he is Vice President, Global Alliances and External Research, Ophthalmology Innovation Center at Santen Inc USA, where he has been instrumental in establishing, nurturing and managing long term partnerships with pharma companies and several global universities. Dr. Sharif serves on numerous committees of many learned Societies (including ISER, elected Trustee of AOPT & Gold Fellow; Gold Fellow of ARVO and Fellow of British Pharmacological Society (BPS)). Dr. Sharif is Editor/Associate Editor/Editorial Board member of many Pharmacology and Ophthalmic journals. He is the recipient of the inaugural Dr. Roger Vogel award for ocular pharmaceutical research (ARVO Foundation, 2104), the recipient of the “Sir James Black Award” for contributions to drug discovery (BPS, 2017), and awarded of the Ernst Barany Prize for outstanding contributions to ocular pharmacology. Dr. Sharif is an Adjunct Professor / Honorary Senior Lecturer / Senior Principal Investigator and graduate Faculty at multiple Universities worldwide. He has also been a PhD candidates supervisor, advisor and mentor to several students at numerous academic institutions. Dr. Sharif has published more than 210 scientific articles, edited 2 books, holds 24 issued US/EU patents, and has filed more than 30 patent applications over the last two decades.
Ocular hypertension, Glaucoma
Scientific Archives is a global publisher initiated with the mission of ensuring equal opportunity for accessing science to research community all over the world. Spreading research findings with great relevance to all channels without any barrier is our goal. We want to overcome the challenges of Open Access with ensured quality and transparency.